Step Therapy: Legal and Ethical Implications of a Cost-Cutting Measure

Sharona Hoffman

Case Western Reserve University School of Law, sharona.hoffman@case.edu

Follow this and additional works at: https://scholarlycommons.law.case.edu/faculty_publications

Part of the Health Law and Policy Commons

Repository Citation

This Article is brought to you for free and open access by Scholarly Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Scholarly Commons.
Step Therapy: Legal, Ethical, and Policy Implications of a Cost-Cutting Measure

SHARONA HOFFMAN

ABSTRACT

The very high and ever-increasing costs of medical care in the United States are well-recognized and much discussed. Health insurers have employed a variety of strategies in an effort to control their expenditures, including one that is common but has received relatively little attention: step therapy. Step therapy programs require patients to try less expensive treatments and find them to be ineffective or otherwise problematic before the insurer will approve a more high-priced option. This article is the first law journal piece dedicated to analyzing this important cost control measure.

This article explores the strengths and weaknesses of step therapy and its legal and ethical implications. It argues that in some cases, step therapy reduces insurers’ drug costs in the short term but causes significant harm to patients that ultimately results in both human suffering and increased long-term health care costs. Some insurers are also less than transparent with patients about their programs, adhere to one-size-fits-all approaches that ignore nuanced clinical and economic evidence, and implement their policies in a discriminatory way. This article examines how several states have responded to step therapy through legislation and discusses review mechanisms that federal law provides for adverse insurance decisions. This article concludes with a detailed set of recommendations. These include legislative interventions to ensure that step therapy programs are sufficiently flexible and responsive to patients’ individual needs and measures to enhance transparency and expeditiously address emerging scientific and economic evidence.

INTRODUCTION

My husband Andy was diagnosed with Parkinson’s disease at the age of fifty-five in October of 2013. Happily, he is managing his disease well and still works full-time as a professor of computer science. He exercises regularly and takes several medications. We are hopeful that the disease will progress slowly and that there are still many good years ahead.

Imagine our dismay when, in late 2016, our pharmacy benefit manager (PBM) informed us that it was denying coverage for the drug that Andy found most helpful and that it had previously covered. The PBM’s explanation was as follows:

1 A pharmacy benefits manager administers the drug benefit program for a health plan. It processes and pays prescription drug claims, negotiates with manufacturers for lower drug prices, and can employ
Your plan approved criteria covers this drug when the patient has tried and had an inadequate treatment response, intolerance, or contraindication to all formulary alternatives for the given diagnosis (or to at least 1 agent within each of a given class of agents when more than 1 class is available for the diagnosis), or when the drug is the only product the patient can use for their condition. Your use of this drug does not meet the requirement.

This was our introduction to step therapy, a policy that requires patients to take cheaper drugs first and find that they fail before being approved for more expensive treatments. After calling several pharmacies, I determined that the drug, at Andy’s dosage, would cost us over $8,000 a year if we were to pay out-of-pocket. Because Andy had already tried several less effective therapies, we undertook an appeal process and were ultimately rewarded with a temporary reprieve. However, our PBM has reserved the right to revisit the matter in the future.

This article is the first law journal piece dedicated to the step therapy phenomenon. Unbeknownst to most patients, step therapy is pervasive in health insurance plans. Step therapy programs raise a variety of compelling legal and ethical challenges that are analyzed in this paper. Although it is often PBMs that institutes step therapy programs (insurers can contract with external PBMs or have their own, internal ones), the remainder of the article will refer to those who operate step therapy programs collectively as “insurers” for the sake of simplicity.

Insurers can hardly be blamed for undertaking initiatives to control their expenditures. Indisputably, the United States suffers from a dramatic and worrisome rise in health care costs.

The question is whether step therapy programs are a sound solution. There is no categorical answer to this query. For some patients, step therapy requirements are reasonable and meet their treatment needs. However, it is not uncommon for step therapy to provide patients with inadequate care that can cause serious harm.

Eitan Kling-Levine, an ulcerative colitis patient, related in a Boston Globe opinion piece that his insurer required that he fail several drugs during a six-month period before approving the physician’s chosen biologic therapy. During that six-month
period, his health deteriorated to such an extent that he ultimately had his colon surgically removed. He speculates that he might have been able to avoid this radical surgery and considerable pain and suffering had he been allowed to take the biologic as soon as his doctor prescribed it.\(^8\) Kathleen Arntsen, a glaucoma\(^9\) patient, stated in an interview that she was required to try two inexpensive drugs over seven weeks before being allowed to use the Travatan Z eye drops that her physician had initially prescribed.\(^10\) She experienced swelling, increased pressure, and loss of vision in her eye and, at the time of writing, was considering having the eye removed because it continued to hurt.\(^11\) She too believes that the delay contributed to her poor outcome.\(^12\)

For patients, receiving the medication that is most effective for them and causes the least severe side effects can make the difference between being homebound and being able to work, care for one’s family, and enjoy life. Working can engender not only financial stability, but also strong self-esteem, social ties, and a sense of purpose, all of which contribute to good mental and even physical health.\(^13\)

When an insurer denies coverage for a drug that a physician selects as the best fit for the patient (in Andy’s case, a drug that he has taken successfully for many months), the patient can suffer severe consequences, such as adverse reactions to a different drug, complications, and deteriorating health.\(^14\) Insurers, in turn, ultimately cover the cost of treatments for these adverse outcomes.\(^15\) Patients who wish to dispute the denial must ask physicians to assist them with an appeal and hope that their doctors have the time and the gumption to do so. Handling such requests is a burdensome task for which physicians do not directly get paid.\(^16\)

Step therapy thus impacts multiple parties with often conflicting agendas. Patients seek treatments that are as safe and effective as possible, want comprehensive insurance coverage, and often expect to be able to choose among different treatment

---

8 Kling-Levine, supra note 7.


11 Id.

12 Id.

13 WORLD HEALTH ORG. & INT’L LABOR ORG., MENTAL HEALTH AND WORK: IMPACT, ISSUES AND GOOD PRACTICES 5 (2000), http://www.who.int/mental_health/media/en/712.pdf [https://perma.cc/2K6Q-RJFS] (“Although it is difficult to quantify the impact of work alone on personal identity, self-esteem and social recognition, most mental health professionals agree that the workplace environment can have a significant impact on an individual’s mental well-being.”).

14 See infra Part I. C.

15 Id.

options. Insurers have a duty to serve their enrollees’ health needs but wish to save costs whenever practicable. Physicians devote themselves to patient care, worry about patient satisfaction and their professional reputations, and wish to minimize cumbersome administrative work. Also influential are pharmaceutical companies that market their products aggressively to healthcare providers and to patients through direct-to-consumer advertising.

Step therapy, therefore, has more complicated implications than initially meet the eye. Step therapy policies should be carefully designed to achieve cost savings while remaining flexible, responsive to patients’ needs, and consistent with relevant clinical data. Insurers should be careful not to strive single-mindedly to reduce short-term costs at the expense of ignoring patients’ overall well-being, physicians’ treatment goals, and the prospect of increased long-term expenditures.

This article proceeds as follows. Part I provides background information about step therapy. It also discusses the need for cost control measures in light of skyrocketing pharmaceutical prices. In addition, it analyzes whether step therapy is effective in meeting cost reduction goals. Part II argues that step therapy raises several legal and ethical concerns. These include lack of transparency, inflexibility that may disregard emerging evidence from precision medicine and other research initiatives, and discrimination. Part III assesses state and federal legislation that is relevant to step therapy. Several states have passed step therapy statutes that outline the circumstances under which insurers must grant waivers and require that they do so expeditiously upon receiving appropriate requests. Federal law in the form of the Employee Retirement Income Security Act of 1974 (ERISA), the Patient Protection and Affordable Care Act (ACA), and the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA) also feature mechanisms for challenging adverse insurance decisions and for the review process that insurers must implement. Part IV develops recommendations to address concerns about step therapy. It proposes, first, that all states enact step therapy laws; second, that federal law specifically address step therapy programs; third that insurers improve transparency by disseminating clear information about step therapy requirements in print and on their websites; fourth, that expert panels such as insurers’ pharmacy and therapeutics committees monitor and incorporate up-to-date scientific and financial evidence into their policies; and fifth, that insurers implement step therapy programs in a non-discriminatory way. Part V concludes the article.


I. STEP THERAPY: WHAT, WHY, AND WHEN

Step therapy is a common cost reduction tool of which many insurance enrollees are unaware. This Part explains step therapy, discusses the need for cost control measures, and analyzes whether step therapy is effective at reducing medical costs.

A. Step Therapy Basics

Step therapy, also called “fail first” policies, require patients to try less expensive treatments and find them to be ineffective or otherwise problematic before the insurer will approve a more costly option.22 According to the American Academy of Dermatology, in 2010, almost sixty percent of commercial insurers had implemented step therapy and, as of 2014, seventy-five percent of large employers had insurance plans with step therapy.23 Some Medicare Part D plans utilize step therapy as well.24

In some cases, step therapy programs require patients to try one or more generic drugs25 before brand name medications are approved.26 In other cases, insurers mandate that patients try a class of drugs that is less costly before allowing a switch to a more expensive class.27

Some insurers publish lists of drugs that are subject to step therapy. Insurers often require step therapy for drugs to treat the following conditions: allergies, asthma, attention deficit hyperactivity disorder, depression, diabetes, gastrointestinal problems, glaucoma, high cholesterol, high blood pressure, insomnia, menopause, multiple sclerosis, osteoporosis, pain, Parkinson’s disease, psoriasis, rheumatoid arthritis, and more.28 Other insurers provide patients with only a generic description of step therapy.29 Even detailed websites, however, can be difficult to navigate, and patients and physicians are very unlikely to scour the insurer’s website before deciding on a treatment plan.

22 Nayak & Pearson, supra note 3, at 1779.


25 Generic drugs are less expensive “copies of brand-name drugs and are the same as those brand name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.” Generic Drugs, FOOD & DRUG ADMIN., https://www.fda.gov/Drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/default.htm [https://perma.cc/8BG4-8UF4] (last updated April 26, 2017).


27 Id.


29 See, e.g., CVSCAREMARK, STEP THERAPY (2017) (on file with author) (“Even though your doctor may prescribe one medicine, treatment guidelines may recommend trying alternative therapy first. If that alternative treatment isn’t effective, you will be eligible for the medicine you were originally prescribed.”).
B. The Need for Cost Control Measures

Insurers’ desire to implement cost control measures is understandable. Prescription drug prices rose 10.9 percent in 2014 and another ten percent in 2015.30 According to the AARP, “[t]he average cost for a year’s supply of medication for someone with a chronic illness has more than doubled since 2006 to over $11,000.”31 The costs of some drugs such as EpiPens and Daraprim have notoriously risen far more precipitously than that. The price of EpiPens, which treat severe allergic reactions, rose from $100 for a two-pack in 2009 to $608 in 2016.32 Turing Pharmaceuticals’ embattled chief executive Martin Shkreli raised the price of Daraprim, a drug to treat infections caused by parasites, by more than 4,000 percent from $18 a pill to $750 a pill.33

Furthermore, insurers worry that some prescribing decisions are driven by pharmaceutical companies’ intensive marketing efforts.34 Whether because of advertising or for other reasons, some physicians do not follow experts’ recommendations for first-choice drugs that are relatively inexpensive.35 For example, one study showed that thirty-five percent of newly diagnosed diabetes patients did not receive metformin, recommended as the initial treatment choice in clinical guidelines.36 A 2013 exposé in the Washington Post revealed that many doctors injected macular degeneration patients with Lucentis at a cost of approximately $2,000 an injection rather than with Avastin, which would cost a mere $50,37 though not all physicians agree about which drug is the better alternative.38

Step therapy is one of several cost-saving measures that insurers employ. Examples of other cost-saving techniques are medical necessity determinations, requirements for

31 Jo Ann Jenkins, Let’s Cut Drug Costs, 58 AARP BULL. 24 (May 2017).
34 Fischer & Avorn, supra note 26, at 802.
35 Id.
38 Macular Degeneration P’ship, Lucentis vs. Avastin, AMD (Nov. 2013), http://www.amd.org/lucentis-vs-avastin/ [https://perma.cc/J8J8-Y6TM] (noting that FDA has not approved Avastin for use in the eye (it is approved to treat colon cancer) but that it is commonly used and has been shown by most studies to be as safe and effective as Lucentis).
prior authorization, quantity limits, and tiering. Medical necessity determinations deny coverage based on an insurer’s determination that the prescribed therapy is not needed to prevent, diagnose, or treat a medical condition. Prior authorization mandates establish that physicians must receive the insurer’s permission to prescribe a drug in order to have the drug covered by the insurance plan. Quantity limits restrict the amount of a particular medication that an insurer will cover over a specific period of time (e.g. only thirty pills per month). Tiering categorizes drugs into tiers and assigns different copayment sums to different drug tiers.

The insurer’s bottom line is not the only thing that is hurt by exorbitant drug prices. Insurers are likely to shift at least some of the costs to patients, raising their premiums, charging higher copayments, and increasing deductibles. Therefore, patients themselves have much to lose from growing coverage costs.

In principle, therefore, insurers are justified in pursuing initiatives to control expenditures. But cost-reduction measures must be implemented thoughtfully and responsibly, and step-therapy may all too often do more harm than good.

C. Does Step Therapy Reduce Insurers’ Expenses?

Step therapy aims to reduce insurers’ costs without compromising patient care. Whether it consistently does so in practice is debatable.

Some studies have shown meaningful cost savings. For example, a study of blood pressure medications found that a step therapy program saved 13 percent in drug costs. Likewise, a study involving antidepressants concluded that step therapy

---


42 Id.


generated savings of nine percent.\textsuperscript{46} A literature review published in 2011 concluded that step therapy generally led to statistically significant savings in drug costs, though this was not clearly true in the case of antipsychotics.\textsuperscript{47} Furthermore, step therapy policies for nonsteroidal anti-inflammatory drugs and proton pump inhibitors\textsuperscript{48} reduced drug costs without causing an increase in consumption of other medical services.\textsuperscript{49}

Other studies, however, cast doubt on whether step therapy achieves significant overall expense reductions. A 2010 article that analyzed 15 prior studies confirmed that step therapy lowered drug costs for insurers.\textsuperscript{50} However, it concluded that it generally does not reduce, and may even increase, overall health care expenditures.\textsuperscript{51} The researchers explained that patients subject to step therapy restrictions often stop taking medication or underutilize it, a phenomenon that can explain why drug costs drop while other health care costs rise as a patient’s condition goes untreated.\textsuperscript{52}

Several additional studies support the conclusion that step therapy is often unsuccessful in reducing long-term medical costs. A study focusing on treatment for attention deficit hyperactivity disorder concluded that step therapy resulted in no overall cost difference but did cause patients to experience treatment delays and to underutilize needed drugs.\textsuperscript{53} A study of a step therapy policy involving Pregabalin, a nerve pain medication, found that the policy decreased use of Pregabalin but did not reduce total health care costs for patients.\textsuperscript{54} An economic model designed to determine the cost implications of a generic step therapy program for selective serotonin reuptake inhibitors (SSRIs) to treat anxiety disorders predicted an adverse cost outcome.\textsuperscript{55} Drug costs would decrease by $0.26 per patient per month but medical costs would increase by $0.32 per patient per month.\textsuperscript{56}


\textsuperscript{49} Motheral, \textit{supra} note 47, at 143.

\textsuperscript{50} Rashad I. Carlton, Review of Outcomes Associated With Formulary Restrictions: Focus on Step Therapy, 2 AM. J. PHARMACY BENEFITS 50, 56–7 (2010).

\textsuperscript{51} Id.

\textsuperscript{52} Id.


\textsuperscript{55} Patt Ellen Panzer et al., Implications of an SSRI Generic Step Therapy Pharmacy Benefit Design: An Economic Model in Anxiety Disorders, 11 AM. J. MANAGED CARE S370, S370 (2005).

\textsuperscript{56} Id. at S375–76.
It is worth emphasizing that step therapy has the potential to severely exacerbate health problems.\textsuperscript{57} As noted above, patients who do not receive their drug of choice may stop taking medication or take it only intermittently, and thus their health may decline.\textsuperscript{58} Moreover, physicians may have good reasons to select a particular drug for a patient. A different (cheaper) medication may be less effective for a patient or cause debilitating side effects.\textsuperscript{59}

For example, Dr. Benjamin Kopp, a pediatric pulmonologist, relates: “I have prescribed certain pulmonary medications for a toddler, only to have the health insurer insist on a lower cost medication that is designed for a teenager. This shows me the decisions about step therapy requirements do not involved pediatricians, asthma specialists, and pharmacists who know the most about the medications.”\textsuperscript{60} Dr. Kopp further asserts that switching a child who was stable on one drug to a different asthma drug can cause complications and hospitalizations.\textsuperscript{61}

The same is true for many other illnesses. In the case of Parkinson’s disease, patients and their physicians must carefully weigh the benefits and risks of various drug options because medications can cause hallucinations, extreme fatigue, compulsive and impulsive behavior, gastrointestinal problems, and more.\textsuperscript{62} Patients have different levels of tolerance for these side effects, and some patients wish to avoid the risk of certain side effects at all costs and choose their medication accordingly.

At times, even switching from a brand name to a generic of the same drug can have adverse consequences because of lower efficacy of the generic drug, allergic reactions, or patients’ unwillingness to take a new pill that looks different from the one to which they are accustomed.\textsuperscript{63} In reality, generics are not an exact duplicate of the original, brand name drug.\textsuperscript{64} The Food and Drug Administration (FDA) acknowledges that it is “aware that there are reports noting that some people may experience an undesired effect when switching from a brand-name drug to a generic formulation or from one


\textsuperscript{59} Nayak & Pearson, \textit{supra} note 3, at 1780.


\textsuperscript{61} Id.


\textsuperscript{64} Katherine Eban, \textit{Are Generics Really the Same as Branded Drugs?} FORTUNE (Jan. 10, 2013), http://fortune.com/2013/01/10/are-generics-really-the-same-as-branded-drugs/ [https://perma.cc/GWV7-DWFB].
generic drug to another generic drug.65 Problems may arise because of quality discrepancies among different manufacturers. For example, in 2007 FDA noted variations among levothyroxine pills66 produced by different pharmaceutical companies.65 Because of concerns about the stability of the drug, FDA required that the potency of levothyroxine products degrade by no more than five percent over their shelf lives.68 Likewise, a study of the antipsychotic drug olanzapine found significantly lower concentrations of the medicine in patients who had switched from the brand name to the generic form of the drug.69 It is also noteworthy that generic drugs need not contain the same inactive ingredients70 as brand name products,71 so patients who tolerated the original drug well may have an adverse reaction to an inactive component of the generic substitution.72

In addition, patients who have to try multiple drugs sequentially before being approved for the doctor’s drug of choice may suffer symptoms of drug withdrawal and find it difficult to adjust to new medications.73 This is true both for patients who initially took the doctor’s recommended drug but were later subjected to step therapy requirements and for those who immediately were denied coverage and may try several less costly drugs with which they are dissatisfied before requesting a step therapy waiver. The Mayo Clinic lists the possible symptoms of antidepressant withdrawal (especially if the drug is stopped too quickly) as follows: anxiety, insomnia or vivid dreams, headaches, dizziness, tiredness, irritability, flu-like symptoms, including achy muscles and chills, nausea, electric shock sensations, return of


67 Id.

68 Id.; see also, Michael Bihari, Brand Name and Generic Levothyroxine: Is There a Difference between Brand Name and Generic Thyroid Drugs?, VERYWELL, (May 28, 2017), https://www.verywell.com/levothyroxine-brand-name-vs-generic-versions-1124055 [https://perma.cc/SCU3-33M8].


72 Rong-Kun Chang et al., Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products, 15 AM. ASS’N PHARMACEUTICAL STUD. J. 41, 45 (2013) (“Special attention should be paid to the use of fragrance in the formulation, because 1% of the general population suffers from fragrance allergies”).

depression symptoms. All of these can be debilitating for patients who are trying to work and lead normal lives.

Thus, step therapy may often save costs in the very short term but increase costs in the long term because of complications, health deterioration, and the patient’s need to seek more and more medical care in order to find relief. Some insurers may ignore the risk of long-term consequences in hope that when these materialize, the patient will be working for a different employer with a different policy or will have turned 65 and enrolled in Medicare. But ignoring the risks of step therapy is bad policy for patients, health care providers, and the American public at large.

II. LEGAL, ETHICAL, AND POLICY IMPLICATIONS OF STEP THERAPY

Beyond the possibility of poor health outcomes, step therapy raises several legal and ethical concerns. First, insurers may not be transparent about step therapy requirements. Second, the one-size-fits-all approach is in tension with the emerging trend of precision medicine. Third, insurers may apply the policy in a discriminatory fashion that violates federal anti-discrimination mandates.

A. Lack of Transparency

Transparency is a core value in health care. As the American Health Policy Institute explains, “[i]n a fully transparent market, measures that disclose the relative cost, quality and customer experience for all elements of the health care supply chain would be publicly available.” Full transparency would allow consumers to become more informed purchasers of health plans and health care services and to demand market accountability. Without transparency it is nearly impossible “to create a rational marketplace in which those who provide superior value are rewarded with more business, and those who don’t suffer the consequences.”

Assuming that Andy’s experience is representative, patients often have no idea that their insurer has implemented a step therapy program and remain ignorant of which drugs are subject to it. The news that an insurer has refused to pay for a prescribed

---

74 Mayo Clinic, supra note 73.
75 Burns, supra note 57.
78 Id. at 2.
79 Id. at 4.
80 Id.
81 See supra notes 28–29 and accompanying text.
drug comes as an unwelcome surprise for the patient and prescribing provider, who must decide whether to fight the decision or opt for another treatment.\textsuperscript{82}

Moreover, patients may find that busy medical practices are less than enthusiastic about engaging in combat with insurers over denials, an activity for which they do not directly get paid.\textsuperscript{83} A 2011 Government Accountability Office report indicated that between 11 and 24 percent of claims and preauthorization requests were denied in the three states that were studied.\textsuperscript{84} Health care providers, therefore, may feel overwhelmed by requests for assistance with patient appeals.

Full transparency about step therapy requirements may enable individuals to choose more wisely among different health plans. Admittedly, however, many will not have a choice because the majority of employers offer only one insurance plan.\textsuperscript{85} Even those whose employers offer several options may find that all plans are served by the same PBM. In fact, three large PBMs, ExpressScripts, CVSHealth (also known as CVS Caremark), and OptumRx control approximately 80 percent of the market.\textsuperscript{86}

At the very least, however, transparency will enable patients and their doctors to make more informed decisions about medical care. When physicians and patients initially decide on a course of treatment, they must be aware of any limitations that the insurer is likely to impose in order to avoid any harmful treatment delays or disruptions.

\textbf{B. At Odds with Precision Medicine Approach}

Precision medicine can be defined as an “approach for disease prevention and treatment that takes into account individual differences in lifestyle, environment, and biology.”\textsuperscript{87} President Obama’s Precision Medicine Initiative, launched in January of 2015, has fueled precision medicine,\textsuperscript{88} and emerging resources such as genetic technologies, large-scale biologic and electronic health record databases, and

\begin{itemize}
  \item \textsuperscript{83} PFIZER, supra note 16.
  \item \textsuperscript{84} GOV’T ACCOUNTABILITY OFFICE, PRIVATE HEALTH INSURANCE: DATA ON APPLICATION AND COVERAGE DENIALS (Mar. 17, 2011), http://www.gao.gov/new.items/d11268.pdf [https://perma.cc/4Z4-B6R7]. Of the six states on which the report focused, only three captured this data, namely, California, Maryland, and Ohio. Id. at 3, 17.
  \item \textsuperscript{85} K AISER FAMILY FOUND. & HEALTH RES. & EDUC. TR., 2016 EMPLOYER HEALTH BENEFITS SURVEY 72 (Sept. 14, 2016), http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-Annual-Survey [https://perma.cc/5D6F-BJSU] (“Most firms that offer health benefits offer only one type of health plan (83%)” and that “[l]arge firms are more likely to offer more than one plan type than small firms.”).
  \item \textsuperscript{86} State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces: Hearing Before the Subcomm. on Regulatory Reform, Commercial and Antitrust Law of the H. Comm. on the Judiciary, 114th Cong. 25 (2015) (statement of David A. Balto); Wapner, supra note 1 (stating that the three PBMs “control an estimated 80 to 85 percent of the market”).
  \item \textsuperscript{87} \textit{About the All of Us Research Program}, NAT’L INSTS. HEALTH, https://allofus.nih.gov/about/about-all-us-research-program [https://perma.cc/U6Q-Q779] (last visited June 16, 2017).
  \item \textsuperscript{88} See Fact Sheet: President Obama’s Precision Medicine Initiative, WHITE HOUSE OFF. PRESS SECRETARY (Jan. 30, 2015), https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative [https://perma.cc/W6HC-4VNS].
\end{itemize}
advanced computational tools make precision medicine a promising approach. The Trump administration continues to support the initiative and calls it the All of Us Research Program.

Precision medicine aims to enable physicians to tailor treatment to patients’ attributes and characteristics. Thus, physicians may be able to match treatments to patients based on factors such as genetic variations, microbiome composition, medical histories, lifestyles, and diet. Precision medicine is already improving cancer treatments as physicians have begun to test patients and their tumors for particular genetic markers to determine what treatment, if any, is appropriate. For example, the breast cancer drug trastuzumab (Herceptin) has been found to work only for women whose tumors have a particular genetic profile called HER-2 positive, and lung cancer patients whose tumors are positive for EGFR mutations receive the drugs gefitinib (Iressa) and erlotinib (Tarceva) that target this mutation. Precision medicine has yielded benefits in other areas as well, such as treatments for cystic fibrosis and reproductive health.

By contrast, step therapy constitutes a one-size-fits-all approach. Insurers require that, as a rule, doctors prescribe a particular medication before turning to more expensive alternatives. In some cases, such mandates may prevent physicians from harnessing new knowledge derived from precision medicine research and customizing treatment protocols to fit their patients’ particulars. Such inflexibility could ultimately

89 Francis S. Collins & Harold Varmus, A New Initiative on Precision Medicine, 372 N. ENGL. J. MED. 793, 793 (2015); Larry J. Jameson & Dan L. Longo, Precision Medicine—Personalized, Problematic, and Promising, 372 N. ENGL. J. MED. 2229, 2229–30 (2015). Nevertheless, commentators also note various barriers to implementing precision medicine in the clinical setting and caution that expectations must be realistic. Michael J. Joyner & Nigel Paneth, Seven Questions for Personalized Medicine, 314 J. AM. MED. ASS’N. 999, 1000 (2015) (“Even though personalized medicine will be useful to better understand rare diseases and identify novel therapeutic targets for some conditions, the promise of improved risk prediction, behavior change, lower costs, and gains in public health for common diseases seem unrealistic.”).


93 WHITE HOUSE, supra note 91.

94 Collins & Varmus, supra note 89, at 794; Jameson & Longo, supra note 89, at 2229.


97 See supra Part I. A.
raise health care costs. Some patients may receive therapies that are doomed to be suboptimal for them and that doctors versed in up-to-date research outcomes would not have prescribed absent step therapy restrictions.

C. Potential Discrimination

Step therapy can constitute unlawful discrimination if insurers do not thoughtfully select the medications that are subject to this policy. Insurance policies are governed by a variety of state and federal laws that protect people with disabilities, including the Americans with Disabilities Act of 1990 (ADA) and the ACA.

Almost half of all Americans are covered by employer-provided health insurance. Title I of the ADA prohibits employers from discriminating against qualified individuals because of their disabilities, and this mandate extends to benefits such as health insurance. Likewise, Title II of the ADA prohibits disability discrimination with respect to public services provided by state or local entities, and Title III governs “public accommodations and services provided by private entities.” These titles thus apply to insurance policies that individuals obtain through the private market or state programs (rather than employers). Note that Medicare and Medicaid are federal programs and are covered by Section 504 of the Rehabilitation Act, but this law’s anti-discrimination mandate is identical to the ADA’s.

---

98 See supra Part I. C.
101 Health Insurance Coverage of the Total Population, HENRY J. KAISER FAMILY FOUND. (2015), http://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D [https://perma.cc/T7L4-69Y4] (indicating that 49% are covered by policies that are provided by employers).
102 42 U.S.C. § 12112(a) (2010). The provision reads:
   No covered entity shall discriminate against a qualified individual with a disability because of the disability of such individual in regard to job application procedures, the hiring, advancement, or discharge of employees, employee compensation, job training, and other terms, conditions, and privileges of employment.
103 42 U.S.C. § 12132 (2010) providing that
   No individual shall be discriminated against on the basis of disability in the full and equal enjoyment of the goods, services, facilities, privileges, advantages, or accommodations of any place of public accommodation by any person who owns, leases (or leases to), or operates a place of public accommodation.
   See also 42 U.S.C. § 12131 (defining a “public entity” as including any instrumentality of a state or local government).
104 42 U.S.C. § 12182 (2010). Title III provides that
   No individual shall be discriminated against on the basis of disability in the full and equal enjoyment of the goods, services, facilities, privileges, advantages, or accommodations of any place of public accommodation by any person who owns, leases (or leases to), or operates a place of public accommodation.
   Title III “public accommodations” include banks, insurance offices, private educational institutions, sales establishments, service establishments, and many other private entities. 42 U.S.C. § 12181(7) (2010); see also Sharona Hoffman, AIDS Caps, Contraceptive Coverage, and the Law: An Analysis of the Federal Anti-Discrimination Statutes’ Applicability to Health Insurance, 23 CARDOZO L. REV. 1315, 1330–33 (2002) (discussing the applicability of the ADA’s Title I and Title III to insurance policies).
The ADA includes a provision that specifically addresses insurers. Section 501(c) permits insurers to underwrite, classify, or administer risks and to establish the terms of bona fide benefit plans in a manner that is not inconsistent with state law. Nevertheless, it prohibits insurers from adopting practices that are “a subterfuge to evade the purposes” of the law. As I have argued in prior scholarship, Section 501(c) obligates insurers “to provide a cost-based justification for discriminatory benefit limitations or exclusions and provides a defense only for those who can do so.”

Consequently, insurers who select particular conditions for step therapy but exclude others to which step therapy could apply could be violating the ADA’s anti-discrimination mandate. For example, insurers might implement a step therapy requirement for anti-depressants but not for diabetes or asthma, and this choice could constitute discrimination against mental health patients. Indeed, a 2015 Connecticut report (that did not focus specifically on step therapy) found that the state’s largest managed care insurers denied approximately one in 12 initial requests for mental health services, a rate that represented approximately a 70 percent increase between 2013 and 2014. By contrast, during the same two years, the denial rate for overall health services claims declined slightly. To avoid liability, insurers should be able to articulate actuarial and medical reasons for the structure of their step therapy programs. To that end, they might require that patients first try (or switch to) an inexpensive drug only in cases in which there is strong evidence that the inexpensive medication, for most patients, is at least as effective as more costly alternatives, unless the physician can identify specific reasons for an exemption (e.g. an allergy or prior history of failure with the drug).

The ACA likewise has an anti-discrimination provision. Section 1557 of that law prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in health programs or activities that receive federal financial assistance or are run by a federal executive agency. Thus, the ACA’s anti-discrimination mandate

---

No otherwise qualified individual with a disability in the United States . . . shall, solely by reason of his or her disability, be excluded from the participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance or under any program or activity conducted by any Executive agency.

106 42 U.S.C. § 12201(c) (2010).
107 Id.
108 Id.
109 Hoffman, supra note 104, at 1334.
111 Id.
112 See Nayak & Pearson, supra note 3, at 1782–84 (discussing the ethical implications of various scenarios in which a trial of inexpensive drug A might be required before approval of expensive drug B).
113 42 U.S.C. § 18116 (a) (2010). The provision reads:

[A]n individual shall not, on the ground prohibited under title VI of the Civil Rights Act of 1964 (42 U.S.C. 2000d et seq.), title IX of the Education Amendments of 1972 (20 U.S.C. 1681 et seq.), the Age Discrimination Act of 1975 (42 U.S.C. 6101 et seq.), or section 794 of title 29, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under, any health program or activity, any part of which is receiving Federal financial assistance, including credits, subsidies, or contracts of

---
extends to all insurers that receive federal support such as payments through Medicare Part D or the ACA Health Insurance Marketplaces.114 This provision too should limit insurers’ ability to pick and choose arbitrarily among health conditions that are subject to step therapy protocols.

The ADA, Rehabilitation Act, and the ACA provide aggrieved individuals with a private cause of action.115 Consequently, patients who believe they suffered harm because of discriminatory step therapy policies could potentially sue their insurers or employers who provided the allegedly discriminatory insurance benefit.

III. STATE AND FEDERAL LEGISLATION AFFECTING STEP THERAPY

The state and federal legislatures have not ignored the difficulties that some patients face in obtaining insurance coverage for their treatments. Some states have passed laws that specifically address step therapy. Both states statutes and federal law establish review mechanisms for insurance coverage denials. This Part analyzes these protections and the extent to which they apply to different types of insurance plans. It examines state step therapy laws, ERISA, the ACA, and the MMA.

A. State Step Therapy Legislation

The states have begun to respond to the step therapy phenomenon with legislation that governs how insurers apply these policies. As of mid-2017, 14 states had passed legislation addressing step therapy,116 and at least 12 others had bills under consideration.117


117 Id. The states are Florida, Georgia, Massachusetts, Maine, Minnesota, New Mexico, Ohio, Oregon, Rhode Island, Texas, Utah, and Virginia.
No state law prohibits step therapy requirements altogether. Instead, the statutes establish step therapy exemptions, require expedited review of physicians’ requests for waivers, and/or limit the duration of step therapy protocols.

Some provisions are brief and offer little guidance. For example, Arkansas requires only a “clear and convenient process to expeditiously request an override” of step therapy requirements, and California mandates that such requests be handled in the same manner as requests for prior authorization.

Other states have more detailed provisions that place restrictions upon insurers. Illinois has enacted a typical step therapy statute. It requires insurers to approve or deny requests for exemptions within 72 hours of receiving the request and to provide an explanation and information regarding alternative drugs and appeals in case of denial. It further provides that:

(c) A step therapy requirement exception request shall be approved if:
1. the required prescription drug is contraindicated;
2. the patient has tried the required prescription drug while under the patient’s current or previous health insurance or health benefit plan and the prescribing provider submits evidence of failure or intolerance; or
3. the patient is stable on a prescription drug selected by his or her health care provider for the medical condition under consideration while on a current or previous health insurance or health benefit plan.

Furthermore, approvals must be honored for at least 12 months or until renewal of the plan.

Mississippi establishes an additional limitation, which is that “the duration of any step therapy or fail-first protocol shall not be longer than a period of thirty (30) days when the treatment is deemed clinically ineffective by the prescribing practitioner.” If the physician believes, based on sound clinical evidence, that the originally

---

118 Id.
119 Nayak & Pearson, supra note 3, at 1779.
120 Ark. Code Ann. § 23-99-1115 (c)(1) (2015); see also W. Va. Code, § 33-16-3aa (2016) (requiring a “clear and convenient process to request a step therapy exception determination” that is easily accessible on the insurer’s website); Wash. Rev. Code § 69.41.190(2)(c)(iii) (2011) (“[T]he endorsing practitioner shall have an opportunity to request as medically necessary, that the brand name drug be prescribed as the first course of treatment.”).
121 Cal. Ins. Code § 10123.197(a) (West 2016); see supra note 41 for explanation of prior authorization.
122 Ill. Comp. Stat. Ann. 134/45.1(b)(2) (2018); see also N.Y. Pub. Health Laws § 4903.3 (2017) (providing that if “the health of the insured is in serious jeopardy without the prescription drug or drugs prescribed by the insured’s health care professional, the step therapy protocol override determination shall be granted within twenty-four hours of the receipt of information.”).
prescribed medication takes longer than 30 days to become effective, the patient may be required to take the originally prescribed medication for an additional seven days.\footnote{Miss. Code Ann. § 83-9-36(2) (2012).}

For its part, the federal Medicare program also provides guidance regarding step therapy. Medicare allows prescribing clinicians to submit a request for an exception along with a supporting statement if “the alternative(s) . . . required to be used in accordance with step therapy has (have) been or is (are) likely to be less effective or have adverse effects.”\footnote{Exclusions, Ctrs. Medicare & Medicaid Servs. (Nov. 29, 2016), https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Exceptions.html [https://perma.cc/LJ7L-69HW]; 42 C.F.R. § 423.578(b) (2016).}

\begin{align*}
\text{The plan sponsor must then provide notice of its benefits decision within 72 hours or 24 hours in the case of expedited requests.} & \text{128}
\end{align*}

\textbf{B. The ERISA Problem}

ERISA is a federal law that governs benefit plans that are established and maintained by employers.\footnote{Exceptions, Ctrs. Medicare & Medicaid Servs. (Nov. 29, 2016), https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Exceptions.html [https://perma.cc/LJ7L-69HW]; 42 C.F.R. § 423.578(b) (2016).}

Employer-provided health plans cover 49 percent of Americans and thus are an extremely important component of the insurance landscape.\footnote{Health Plans & Benefits: ERISA, Dep’t Labor (June 22, 2017), https://www.dol.gov/general/topic/health-plans/erisa [https://perma.cc/J8Y3-MPZW].}

ERISA’s preemption clause prohibits insurance enrollees from pursuing state law claims and remedies.\footnote{Id. at 735 n. 14.}

Specifically, it states that ERISA “shall supersede any and all State laws insofar as they may now or hereafter relate to any employee [health] benefit plan.”\footnote{Cromwell v. Equicor-Equitable HCA Corp., 944 F. 2d 1272, 1275–76 (6th Cir. 1991); Sharona Hoffman, A Proposal for Federal Legislation to Address Health Insurance Coverage for Experimental and Investigational Treatments, 78 Or. L. Rev. 203, 241–42 (1999).}

Consequently, individuals may not bring actions against insurers based on tort, contract, and other state common law theories, including lawsuits for harm caused by treatment delays associated with step therapy protocols.\footnote{Id.}

However, the statute includes a significant preemption exception. ERISA’s savings clause provides that ERISA does not preempt state statutes that regulate insurance.\footnote{29 U.S.C. § 1144(a) (2010).}

Thus, for example, in 1985 the Supreme Court held that a Massachusetts statute mandating that group insurance policies provide particular minimum benefits was not preempted by ERISA.\footnote{Metropolitan Life Ins. Co. v. Massachusetts, 471 U.S. 724 (1985).}

Because of the savings clause, state statutes governing step therapy in principle would survive ERISA preemption.

The savings clause, however, is limited in its reach because of another ERISA provision called the “deemer clause.”\footnote{Id. at 735 n. 14.}

This clause establishes that state laws regulating insurance \textit{are} preempted with respect to self-funded health insurance.
Employers with self-funded plans collect premiums and pay all medical claims themselves, though they may use a third party to do administrative work for the plan. Step therapy statutes and other state health insurance laws, therefore, cannot be enforced with respect to self-funded plans. According to the Henry J. Kaiser Family Foundation, in 2016, 61 percent of workers were enrolled in self-funded health plans, which are particularly popular among large companies. Consequently, the majority of individuals with employer-provided health plans cannot benefit from the protection of state step therapy laws.

### C. Other Legislative Protections

Fortunately, all insured individuals are entitled to a review process for decisions with which they disagree. This right is furnished by ERISA and by the ACA.

ERISA requires that covered insurers afford participants whose medical claims are denied a “full and fair review” of adverse decisions. Federal regulations provide detailed guidance concerning such appeals, which may consist of two different levels of review. Because this right is created by federal law (not state law), anyone enrolled in an employer-provided plan is entitled to a review of claim denials, including individuals in self-insured health plans and those in states without step therapy statutes.

The ACA also addresses health insurance appeals, and unlike ERISA, this federal law applies to all health insurance consumers, whether or not their policies are provided by employers. The provision requires that at a minimum, insurers do the following: 1) have an internal claims appeals process; 2) provide an easily understood notice to enrollees regarding internal and external review opportunities and any available assistance for these processes; and 3) permit enrollees to review their files, present evidence and testimony, and enjoy continued coverage until their appeals are decided.

It is important to note that the ACA mandates that insurers offer not only internal reviews but also external ones. External reviews are performed by independent third parties that are not associated with the health insurance plan.

---

142 See supra Part III. B (explaining ERISA preemption).
145 Id. at § 300gg-19(b).
External reviews must comply with state external review laws that at the very least include “the consumer protections set forth in the Uniform External Review Model Act promulgated by the National Association of Insurance Commissioners.”

Medicare also enables participants to appeal unfavorable decisions. Pursuant to the MMA, it establishes a five-level appeal process for those who disagree with coverage decisions. The steps include: 1) redetermination from the plan; 2) review by an independent review entity; 3) a hearing before an administrative law judge; 4) review by the Medicare Appeals Council; and 5) judicial review by a federal district court.

Patients’ success rates on appeal are encouraging. According to a 2011 federal government report, insurance denial reversals ranged between 39 and 59 percent on internal appeal, with an additional 23 to 54 percent reversed or revised as a result of external appeals. The numbers vary significantly by state. The report’s authors noted that they could not determine an overall appeal rate for claim denials, but data from Ohio indicated that in the first quarter of 2010, patients internally appealed only 0.5 percent of coverage denials. It is unclear why patients appealed so infrequently. While some may not have been upset by adverse decisions, it is likely that many others did not know that appealing was an option or did not have the mental ability or energy to initiate appeals. It is possible that news stories about insurance appeals in more recent years have raised the appeal figure.

As helpful as review processes may be for some patients, they can extend over several months. For services not yet received, such as a more expensive drug in a step

---


150 42 U.S.C.A. §§ 1395w-104(f)–(h); 42 C.F.R. § 423.562 (2016).


152 GOV’T ACCOUNTABILITY OFFICE, supra note 84, at 23–24.

153 Id.

154 Id. at 22, n. 45. The report also noted that “aggregate claim denial rates for the three states that we identified as collecting such data ranged from 11 percent in Ohio in 2009 to 24 percent in California in the same year.” Id. at 22.

therapy program, insurers must complete internal appeals within 30 days. Insurers can then take up to 60 days after receiving a request to complete an external review. During these months, the health of a patient who is receiving an inexpensive treatment that is a poor fit for her may deteriorate significantly. Thus, even if the coverage denial is ultimately reversed, the patient may suffer grave consequences from treatment delays.

The ACA does not create a private cause of action for wrongful claim denials, but ERISA does so. Therefore, as a last resort, after exhausting the administrative remedies described above, enrollees covered by ERISA plans can sue insurers to recover benefits to which they are entitled under their policies. Other monetary damages, such as compensatory and punitive damages, are generally not available.

Extensive research revealed no cases in which plaintiffs sued because of adverse decisions associated with step therapy. However, numerous cases involve another cost-control strategy: medical necessity determinations. A 2003 U.S. Department of Health and Human Services report focused on 54 medical necessity cases and found that most often, plaintiffs alleged that insurers arbitrarily and unfairly denied them coverage while approving claims in equivalent cases. According to the report, insurers prevailed in 29 lawsuits and had their decisions reversed in 25 instances.

Litigation is expensive and can occupy many months if not years. It is an ineffectual tool for obtaining swift overrides of step therapy policies. However, it can be helpful

---


158 See Kling-Levine, supra note 7 (relating the author’s experience with step therapy for ulcerative colitis); Kopp, supra note 60 (discussing a pediatric pulmonologist’s frustration with step therapy for children’s asthma treatments); see also infra notes 7–12 and accompanying text.

159 Letter from United States Government Accountability Office to Congressional Recipients regarding Causes of Action under the Patient Protection and Affordable Care Act (Mar. 23, 2012) (“W[e] do not believe that the implementation of the provisions identified in section 3512 of PPACA, including the development, recognition, or implementation of related guidelines and standards, is likely to give rise to new causes of action or claims.”); Christine H. Monahan, Private Enforcement of the Affordable Care Act: Toward an “Implied Warranty of Legality” in Health Insurance, 126 YALE L. J. 1118, 1123 n. 23 (2017). The one exception is the ability to sue for discrimination in violation of Section 1557 of the ACA. See supra notes 113–115 and accompanying text.


163 This does not preclude the possibility that there are unreported step therapy cases.

164 SARAH ROSENBAUM ET AL., MEDICAL NECESSITY IN PRIVATE HEALTH PLANS: IMPLICATIONS FOR BEHAVIORAL HEALTH CARE 19–21 (2003). For an explanation of medical necessity determinations, see supra note 40 and accompanying text.

165 Id. at 21.

166 Id. at 20; see, e.g., Delmarva Health Plan v. Aceto, 750 A.2d 1213, 1218 (Del. Ch. 1999) (holding that an insurer must cover a lung transplant).
for patients who opted to pay for an expensive drug out of pocket after receiving a coverage denial and wish to be reimbursed for their costs.

IV. RECOMMENDATIONS

Patients and physicians have been vocal in expressing their frustration with step therapy.\textsuperscript{167} At the same time, it is undeniable that health care expenses are spiraling upwards, and insurers have good reason to be concerned about treatment costs.\textsuperscript{168} This Part develops a balanced set of recommendations that consider the interests of all stakeholders. It proposes that 1) all states enact step therapy laws that, at minimum, include the elements outlined below; 2) ERISA and the ACA address step therapy programs; 3) insurers improve transparency by disseminating clear information about step therapy requirements in print and on their websites; 4) insurers monitor and incorporate up-to-date scientific and financial evidence into their policies; and 5) insurers implement step therapy programs in a non-discriminatory way.

A. All States Should Enact Step Therapy Statutes

Opponents decry step therapy legislation as an overly-rigid intervention and would prefer to be free of legislative constraints.\textsuperscript{169} In truth, however, it is step therapy itself that is inflexible and a “one-size-fits-all” approach. It categorically requires patients to take particular drugs before being approved for others, no matter what their personal circumstances are.\textsuperscript{170}

State step therapy statutes constitute a measured response to concerns about step therapy.\textsuperscript{171} They do not prohibit it entirely or subject it to cumbersome requirements. Rather, they generally provide patients with an avenue to obtain relief quickly when needed without significantly undermining insurers’ decision-making powers.

All states should enact step therapy statutes. The laws need not be identical but should include the following requirements:

- Approval or denial of requests for exemption within 72 hours of receiving the request or 24 hours if the request is urgent and there is serious risk to the insured’s health.\textsuperscript{172}
- Exemptions to be granted in the following circumstances:
  - The drug is contraindicated (inappropriate because of the patient’s medical history, attributes, or other circumstances);
  - The patient has previously tried the first-step drug, and the prescribing physician submits evidence that the drug was poorly tolerated or ineffective (evidence can come in the form of a physician statement or notations from the patient’s record).

\textsuperscript{167}See Kling-Levine, \textit{supra} note 7; Kopp, \textit{supra} note 60 (discussing a pediatric pulmonologist’s frustration with step therapy for children’s asthma treatments).

\textsuperscript{168}See \textit{supra} Part I. B.

\textsuperscript{169}Fischer, \textit{supra} note 26, at 802.

\textsuperscript{170}See \textit{supra} Part I. A.

\textsuperscript{171}See \textit{supra} Part III. A.

\textsuperscript{172}See N.Y. PUB. HEALTH LAWS § 4903 (3) (2017).
The patient is already stable on the drug selected by the physician.\footnote{215 ILL. COMP. STAT. ANN. § 134/45.1(c) (2018).}

- Inclusion of a clear explanation and information about appeal mechanisms and covered alternative medications when the insurer denies a request for exemption.\footnote{Id. at § 134/45.1(b)(2).}
- Approval of drugs for at least 12 months when the insurer grants requests for exemption.\footnote{Id. at 134/45.1(e).}
- A clear definition of what step therapy “failure” means. For example, the law may require that patients be approved for the physician’s drug of choice if they did not experience adequate improvement or symptom relief, as judged by the physician, after 30 days.\footnote{MISS. CODE ANN. § 83-9-36(2) (2012).} It may also mandate that they try only one alternative drug before approval of the physician-recommended medication.\footnote{See Assembly, No. 1832, State of New Jersey, 215th Leg. § 1.a(2), ftp://www.njleg.state.nj.us/20122013/A2000/1832_11.HTM [https://perma.cc/BJ2C-W8MQ].}

Step therapy laws with lucid guidance will assure physicians that time requesting exemptions will be well-spent and assure patients that they can obtain treatments that will fit their needs. By requiring timely responses, the proposed legislation will prevent harmful treatment delays. Approving exemptions for at least 12 months will save patients and physicians from having to submit waiver requests every few months, a task that can be stressful and onerous. This may be especially helpful for patients with mental health or cognitive difficulties who must ask friends or relatives to assist them in interacting with doctors and insurers and may feel uncomfortable burdening these advocates repeatedly.

Clearly defining step therapy failure is also important.\footnote{See Nayak & Pearson, supra note 3, at 1781 (stating that “what constitutes the failure of the first-step drug can be one of the most contentious aspects of a step therapy policy.”).} Insurers should not have unlimited discretion to demand that patients try cheaper drugs indefinitely or try multiple drugs that do not work well for them. Such trials can severely impact patients’ health, comfort, and ability to function.\footnote{See supra notes 7–12 and accompanying text.}

State statutes should limit the duration of first-step drug trials and the number of drugs that must be taken before approval of the physician’s drug of choice.

A complicating factor is that it is not always clear whether a drug has “failed.” In the case of drugs that treat pain, discomfort, or certain mental health problems, success is judged by patients’ own assessment of whether they feel better. Does the drug relieve the pain? Does the drug adequately reduce the symptoms of Parkinson’s disease, such as tremor and rigidity? Is the patient less anxious or depressed? If the answers are negative, patients will return to their doctors and seek further care. It is therefore important that insurers rely on physicians’ attestations regarding the failure of drugs instead of attempting to formulate objective criteria of their own.
B. Federal Law Should Address Step Therapy

As noted above, state step therapy statutes do not govern employer-provided self-funded health insurance plans because of ERISA’s deemer clause. The majority of American workers and their families are enrolled in self-funded plans, and thus state law does not protect them. Consequently, step therapy provisions should be incorporated into federal law as well.

ERISA itself could address step therapy in its “Claims Procedure” section that mandates a “full and fair review” of adverse insurance decisions. The provision should be detailed and include the requirements described above.

While Medicare regulations already provide step therapy guidelines for Medicare plans, the ACA should do so for all other insurance policies. The law could furnish step therapy guidelines in a new subpart of its “Appeals Process” provision. However, given the current Congress’ efforts to repeal the ACA, the law’s future is uncertain, and it is unlikely that any of its provisions will be expanded in the near term.

C. Improving Transparency

Insurers should be fully transparent about their step therapy requirements and should disseminate clear and readable information about them through their websites and printed materials. They should keep in mind that 50 percent of adults cannot understand a book written at an eighth-grade level, and thus informational materials should be written at a sixth-grade reading level. Insurers should be careful to educate both patients and physicians about step therapy policies. They should also ensure that their websites include tools that enable users to search for restrictions that apply to particular drugs. Medical appointments will be more productive if physicians and patients know to take step therapy requirements into account as they consider treatment alternatives. Physicians who feel strongly that specific drugs are best for patients despite contrary step therapy constraints could immediately initiate waiver requests in order to minimize delays and frustrations (and one hopes they will be willing to invest the time in doing so). Physicians who have no objections to insurers’ preferences could explain them to patients and tailor their recommendations accordingly.

Existing legislative guidelines already embrace the value of transparency. ERISA requires insurers to furnish participants with “summary plan descriptions.”

180 See supra notes 136–139 and accompanying text.
181 See supra note 139 and accompanying text.
183 See Part IV. A.
184 See 42 C.F.R. §§ 423.568(b), 423.572(a), 423.578(b) (2016).
185 42 U.S.C. § 300gg-19 (2010). Note that federal regulations already require that insurers who receive a request to review an adverse coverage decision do so within 72 hours or 24 hours in exigent circumstances. 45 C.F.R. §156.122(c)(1)(i)(ii), (2)(ii) (2016).
provision details the “easily understood”\textsuperscript{188} information that enrollees must receive and could be slightly revised to require specific disclosure of step therapy programs.\textsuperscript{189} If the summary plan description is lengthy and participants are unlikely to read it, insurers would be wise to highlight the existence of step therapy policies in a separate newsletter or brochure. In addition, the information should be posted on user-friendly websites.

Several state laws also address transparency and disclosure by health insurers.\textsuperscript{190} For example, a California law requires insurers that use a formulary\textsuperscript{191} to post the formulary on their websites.\textsuperscript{192} A Colorado statute requires the insurance commissioner to develop a website that discloses health insurance price information.\textsuperscript{193} State legislatures could similarly establish disclosure requirements regarding step therapy.

Medicare empowers patients to determine whether specific drugs are subject to insurance restrictions, including step therapy, through a simple search on its website. It offers a page entitled “2017 Drug Finder: Search for Your Prescription Drug across All Medicare Part D or Medicare Advantage Plans.”\textsuperscript{194} Users can enter the name of any drug and obtain a wealth of information about whether and in what manner it is covered by various Medicare plans.\textsuperscript{195} All insurers should enable participants to conduct such searches.

Full disclosure serves not only patients’ interests but also those of insurers. Absent sound reasons for disagreement, patients and physicians who are aware of step therapy guidelines will comply and save insurers the trouble of processing requests for exemption and appeals. By contrast, physicians who cannot easily learn of step therapy restrictions are more likely to prescribe medications for which insurers will deny coverage. Patients who are disappointed and distressed by insurers’ decisions that are contrary to their physicians’ recommendations may then attempt to obtain reversals, creating administrative work and costs for insurers.

\section*{D. Monitor and Incorporate Up-to-Date Scientific and Financial Evidence}

Insurers should frequently review emerging medical evidence to ensure that their step therapy protocols are consistent with patients’ best interests. Step therapy requirements should not become ossified and outdated. For example, if precision medicine studies reveal that individuals with particular genetic mutations or other

\begin{itemize}
\item \textsuperscript{188} Id. at § 1022(a).
\item \textsuperscript{189} Id. at § 1022(b).
\item \textsuperscript{192} CAL. HEALTH AND SAFETY CODE § 1367.205(a)(1) (West 2016).
\item \textsuperscript{193} COLO. REV. STAT. ANN. §§ 10-16-133, 10-16-134.
\item \textsuperscript{195} Id.
characteristics (e.g., age, co-existing diseases, etc.) should take drug B rather than drug A, insurers with step therapy programs mandating initial trials of drug A should respond quickly and alter their coverage guidelines.196

Another source of relevant data is comparative effectiveness research.197 This research, based on studies that compare drugs, devices, or other medical interventions, aims “to inform health-care decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options.”198 As just one example, a recent study published in *JAMA Internal Medicine* focused on treatments for clostridium difficile infection (a bacterium that causes diarrhea).199 When researchers compared the antibiotics vancomycin and metronidazole, they concluded that patients who took vancomycin had a significantly reduced risk of death within 30 days, which suggested that vancomycin should be used as the initial therapy for patients with severe forms of the disease.200 It is obvious that such a finding may require insurers to adjust their step therapy requirements.

Likewise, insurers should review their own financial data to determine whether step therapy requirements are cost-effective. If a first-step drug has a high failure rate or raises overall costs because patients often seek treatment for side-effects and complications, insurers should adjust the requirement in question.201

To these ends, insurers can use their existing pharmacy and therapeutics (P & T) committees.202 Federal regulations detail standards for these committees, relating to their membership, conflicts of interest, quarterly meetings, documentation, and other obligations.203 P & T committees are tasked with reviewing and approving step therapy protocols204 and should be sure to monitor new medical and economic data and modify the protocols as appropriate.205

---

196 See Part II. B (discussing precision medicine).


198 Id.


200 Stevens et al., supra note 199, at 546.

201 See Nayak & Pearson, supra note 3, at 1781.


203 45 C.F.R. § 156.122(a)(3) (2016). Members must “represent a sufficient number of clinical specialties,” be composed of a majority of individuals who are pharmacists or “health care professionals who are licensed to prescribe drugs,” and be prohibited from voting on a matter concerning which they have a conflict of interest. In addition, at least 20 percent must “have no conflict of interest with respect to the issuer and any pharmaceutical manufacturer.” Id. at § 156.122(a)(3)(i).

204 Id. at § 156.122(a)(3)(iii)(F).

205 Id.
E. Avoid Discrimination

Step therapy policies should be equitable and non-discriminatory.\(^{206}\) This is not to say that insurers should subject every possible drug to step therapy requirements to avoid allegations of discrimination. Rather, step therapy policies must be thoughtful and well-supported by scientific and financial evidence. Thus, if patients question why a particular drug is subject to restrictions while others are not, insurers must be able to articulate sound justifications for their implementation decisions.

V. CONCLUSION

Insurers’ concern about the rapidly rising cost of medical care is warranted, and they cannot be condemned for establishing cost-control measures.\(^ {207}\) In her best-selling book, *An American Sickness: How Healthcare Became Big Business and How You Can Take It Back,*\(^ {208}\) Elisabeth Rosenthal details myriad reasons for the United States’ exorbitant health care prices. She also offers a variety of solutions,\(^ {209}\) as have many other commentators.\(^ {210}\)

Step therapy is an intervention that is favored by the majority of U.S. insurers.\(^ {211}\) Often, patients suffer no ill consequences from step therapy policies. For example, many patients tolerate generic drugs just as well as they tolerate brand name drugs.\(^ {212}\)

In other instances, however, step therapy promotes neither patient interests nor the insurer’s economic goals. Patients may suffer grave harms when they do not receive their physician’s drug of choice because of step therapy constraints.\(^ {213}\) These can include medical complication as well as severely diminished functionality, which in turn can result in an inability to work, financial difficulties, depression, and health problems stemming from a sedentary and inactive lifestyle.\(^ {214}\) Thus, step therapy at times is penny wise but pound foolish.

\(^{206}\) See Part II. C (discussing potential discrimination).

\(^{207}\) See Part I.B (discussing the need for cost control measures).

\(^{208}\) ELISABETH ROSENTHAL, AN AMERICAN SICKNESS: HOW HEALTHCARE BECAME BIG BUSINESS AND HOW YOU CAN TAKE IT BACK (Penguin Press 2017).

\(^{209}\) Id. at 241–327.


\(^{211}\) See Part I. A (providing background information regarding step therapy).


\(^{213}\) See supra note 57–74, 167–12 and accompanying text.

This article has argued for a nuanced approach to improving step therapy programs and reducing their risks. \textsuperscript{215} Insurers should establish expeditious and uncomplicated waiver mechanisms, guided by state and federal legislation, so that patients who truly need a more expensive drug can quickly obtain it and doctors are minimally burdened by administrative demands. Insurers must also enhance transparency, respond to emerging medical and financial evidence that necessitates policy modifications, and be wary of discrimination. \textsuperscript{216}

Finally, the health insurance industry should conduct further research to determine if step therapy is in fact an effective cost reduction tool. \textsuperscript{217} If the programs’ economic benefits do not outweigh the burdens they impose on patients, physicians, and insurers, they should be altered or abandoned. Step therapy should not constitute a bludgeon that is used against patients and their doctors. Instead, it should be a vehicle for all stakeholders to work cooperatively to reduce treatment costs without compromising health outcomes.

\textsuperscript{215} See Part IV.

\textsuperscript{216} Id.